Multicenter study of the effect of GoLimumab On the Remission Induction rate and bio-free remission maintenance rate in early rheumatoid Arthritis.

Multicenter study of the effect of GoLimumab On the Remission Induction rate and bio-free remission maintenance rate in early rheumatoid Arthritis. - GLORIA study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011891

Enrollment

Registered

2013-10-01

Start date

2013-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Golimumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Rheumatoid arthritis who fulfill the 2011 ACR/EULAR classification criteria. 2.Early RA with disease duration of 6 months or less. 3.Who have at least one of the poor prognostic factors; bone erosions, high titer of anti-CCP antibodies, or HAQ score more than 1.0 4.High disease activity of CDAI score more than 22

Exclusion criteria

Exclusion criteria: 1.progressive interstitial lung disease 2.HBV and/or HCV carier 3.History of any biologic DMARDs use 4.Seriou infection, active tuberculosis, demyelinating disease, or congestive heart failure

Design outcomes

Primary

Measure	Time frame
1.Remission induction rate 2.Health assessment questionare 3. Rate of no radiological progression 4. Bio-free remission maintenance rate and duration 5.Maintenance rate of low disease activity after cessation of golimumab 6.Remission induction rate after re-introduction of golimumab in patients with relapse.	—

Countries

Japan

Contacts

Public ContactMamiko Shimizu

St.Marianna University School of Medicine Division of Rheumatology, Department of Internal Medicine

mamiko.shimizu@marianna-u.ac.jp042-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026